Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.54% | -2.18% | -27.10% | -42.97% | -52.19% |
| Total Other Revenue | -33.67% | -40.89% | -46.42% | -34.20% | -23.91% |
| Total Revenue | -11.36% | -26.27% | -39.95% | -38.19% | -39.25% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -11.36% | -26.27% | -39.95% | -38.19% | -39.25% |
| SG&A Expenses | -54.33% | -47.99% | -41.99% | -20.02% | 2.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.51% | -40.44% | -37.50% | -17.52% | 2.45% |
| Operating Income | 46.72% | 41.88% | 37.24% | 14.68% | -9.98% |
| Income Before Tax | 46.66% | 37.02% | 27.68% | 14.20% | 1.78% |
| Income Tax Expenses | -- | 322.58% | -48.39% | -71.43% | -100.00% |
| Earnings from Continuing Operations | 46.58% | 36.99% | 27.68% | 14.21% | 1.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.58% | 36.99% | 27.68% | 14.21% | 1.80% |
| EBIT | 46.72% | 41.88% | 37.24% | 14.68% | -9.98% |
| EBITDA | 43.08% | 41.53% | 40.07% | 18.10% | -5.97% |
| EPS Basic | 73.09% | 56.57% | 41.34% | 23.32% | 5.97% |
| Normalized Basic EPS | 73.13% | 56.57% | 41.33% | 23.32% | 5.96% |
| EPS Diluted | 73.09% | 56.57% | 41.34% | 23.32% | 5.97% |
| Normalized Diluted EPS | 73.13% | 56.57% | 41.33% | 23.32% | 5.96% |
| Average Basic Shares Outstanding | 98.10% | 71.75% | 44.20% | 24.16% | 4.22% |
| Average Diluted Shares Outstanding | 98.10% | 71.75% | 44.20% | 24.16% | 4.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |